# US 8,278,420 B2 · Composition and method for prevention and treatment of type I diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,420 B2
- Document ID: US8278420B2
- Status: Granted
- Kind: B2
- Application number: 11/997,996
- Filed: 2006-08-04
- Published: 2009-01-15
- Granted: 2012-10-02
- Earliest claimed: 2005-08-06
- Assignees: Qinghua Wang
- Inventors: Qinghua Wang; Gerald J. Prud'homme; Mohan Kumar
- Web page: https://patentgrep.com/patent/US8278420B2

## CPC

- C07K 14/605: Glucagons
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/6056: {Antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a fusion protein selected from the group consisting of GLP-1/IgG or variant or fragment thereof and an Ex4/IgG or variant or fragment thereof and an autoimmune suppressor for silencing an autoimmune response against islet beta cells.

## Claims

### Claim 1

A composition for the treatment of type I diabetes in a subject, said composition comprising:
a GLP-1/IgG fusion protein, wherein said GLP-1 polypeptide is selected from the group consisting of GLP-1(7-37)OH, GLP-1(7-36)amide (SEQ ID NO:1), a DPPIV resistant GLP-1 Ala8 mutant and a DPPIV resistant GLP-1 His7 mutant; and the IgG is human IgG2: and
an autoimmune suppressor comprising at least one antigenic target epitope of a pancreatic beta-cell associated antigen for decreasing autoimmunity against islet beta cells, wherein said pancreatic beta-cell associated antigen is pre-proinsulin comprising SEQ ID NO:8, GAD65 comprising SEQ ID NO:9, 10 and/or 11, or pre-proinsulin/GAD65 (PPI/GAD65) comprising SEQ ID NO:8 and SEQ ID NO: 9, 10 and/or 11.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said IgG comprises an Fc portion of the IgG or a fragment or variant of the Fc portion.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising B7-1wa molecule which is a T cell negative regulatory molecule.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said DPPIV resistant GLP-1 Ala8 mutant is GLP-1A8G.
